Tamoxifen therapy has been demonstrated to be efficacy in both pre- and post-menopausal women with ERα+ breast cancer, leading to almost one-half decrease of the 10-year recurrent risk and approximately one-third decrease of death risk [6]. Here, ESR1 is linked to breast carcinoma.